Immuno Oncology Assays Market size is valued at USD 2,798.6 million in 2021 and is expected to grow at a prominent growth rate 12.5% during the forecast period 2022 to 2028. The global market provides a detailed overview of the global Immuno Oncology Assays Market, and that can be segmented by Product Type, by Technology, by Indication, and by Application. By product type, the global Immuno Oncology Assays Market has been segmented into Instruments, Reagents and Kits, Software and Services. The software & services segment is likely to be the largest and fastest-growing segment in terms of type. Based on technology, the global Immuno Oncology Assays Market is segmented into Immunoassay, Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Flow Cytometry Others. Among these, the Polymerase chain reaction (PCR) segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on indication, the global Immuno Oncology Assays Market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer Treatment, Melanoma Cancer, Bladder Cancer, Others. The lung cancer segment accounts for the largest share in 2021. Breast cancer segment is the second-largest share during the forecast period 2022-2028. Based on the Application, the segment has been segregated into Clinical Diagnostics, Research Application. The clinical diagnostics segment is expected to dominate other segments in the global Immuno Oncology Assays Market. Research application segment is expected to witness the highest CAGR during the forecast period according to precision business insights.
In July 2020, The HTG EdgeSeq Pan B-Cell Lymphoma Panel was launched by HTG Molecular Diagnostics, Inc. (US).